Table 6.

Evaluation of CMV infections in seropositive recipients of HCT from donors in the bank of CMVpp65CTLs

HLA restriction of immunodominant CMVpp65CTL from HCT donorNCMV reactivationLevel Of CMV reactivationDiseaseFailed therapy
YesNoNoLow (2-13/slide; <10 000)High >100 >10 000
B0702 25 19 (75%) 10 3 (15%) 2 (8%) 
A 0201 DOM 28 21 (75%) 16 2 (9%) 1 (3.5%) 
A 1101 DOM 1 (100%) 0 (0%) 0 (0%) 
A 0101 DOM 4 (100%) 0 (0%) 0 (0%) 
A 2402 DOM 4 (100%) 0 (0%) 0 (0%) 
A 2601 DOM 2 (50%) 1 (25%) 1 (25%) 
B 0801 DOM 3 (100%) 0 (0%) 0 (0%) 
B 40, 42, 44 DOM HERN Specific 6 (66%) 2 (24%) 1 (11%) 
B 35 DOM 7 (87.5%) 3 (37.5%) 3 (37.5%) *P = .048 
Other HLA A,B,C alleles DOM 13 11 (84%) 2 (15%) 0 (0%) 
HLA DR alleles DOM 14 13 (92%) 7 (50%) 5 (35%) 
HLA restriction of immunodominant CMVpp65CTL from HCT donorNCMV reactivationLevel Of CMV reactivationDiseaseFailed therapy
YesNoNoLow (2-13/slide; <10 000)High >100 >10 000
B0702 25 19 (75%) 10 3 (15%) 2 (8%) 
A 0201 DOM 28 21 (75%) 16 2 (9%) 1 (3.5%) 
A 1101 DOM 1 (100%) 0 (0%) 0 (0%) 
A 0101 DOM 4 (100%) 0 (0%) 0 (0%) 
A 2402 DOM 4 (100%) 0 (0%) 0 (0%) 
A 2601 DOM 2 (50%) 1 (25%) 1 (25%) 
B 0801 DOM 3 (100%) 0 (0%) 0 (0%) 
B 40, 42, 44 DOM HERN Specific 6 (66%) 2 (24%) 1 (11%) 
B 35 DOM 7 (87.5%) 3 (37.5%) 3 (37.5%) *P = .048 
Other HLA A,B,C alleles DOM 13 11 (84%) 2 (15%) 0 (0%) 
HLA DR alleles DOM 14 13 (92%) 7 (50%) 5 (35%) 

or Create an Account

Close Modal
Close Modal